324 related articles for article (PubMed ID: 16785141)
1. Effective new treatments of iron overload in thalassaemia using the ICOC combination therapy protocol of deferiprone (L1) and deferoxamine and of new chelating drugs.
Kontoghiorghes GJ; Kolnagou A
Haematologica; 2006 Jun; 91(6 Suppl):ELT04. PubMed ID: 16785141
[TBL] [Abstract][Full Text] [Related]
2. Effect of deferiprone or deferoxamine on right ventricular function in thalassemia major patients with myocardial iron overload.
Smith GC; Alpendurada F; Carpenter JP; Alam MH; Berdoukas V; Karagiorga M; Ladis V; Piga A; Aessopos A; Gotsis ED; Tanner MA; Westwood MA; Galanello R; Roughton M; Pennell DJ
J Cardiovasc Magn Reson; 2011 Jul; 13(1):34. PubMed ID: 21733147
[TBL] [Abstract][Full Text] [Related]
3. Differential effects of iron chelators on iron burden and long-term morbidity and mortality outcomes in a large cohort of transfusion-dependent β-thalassemia patients who remained on the same monotherapy over 10 years.
Musallam KM; Barella S; Origa R; Ferrero GB; Lisi R; Pasanisi A; Longo F; Gianesin B; Forni GL;
Blood Cells Mol Dis; 2024 Jul; 107():102859. PubMed ID: 38820707
[TBL] [Abstract][Full Text] [Related]
4. Treatment of heart failure in adults with thalassemia major: response in patients randomised to deferoxamine with or without deferiprone.
Porter JB; Wood J; Olivieri N; Vichinsky EP; Taher A; Neufeld E; Giardina P; Thompson A; Moore B; Evans P; Kim HY; Macklin EA; Trachtenberg F
J Cardiovasc Magn Reson; 2013 May; 15(1):38. PubMed ID: 23688265
[TBL] [Abstract][Full Text] [Related]
5. Development of oral iron chelator L1.
Hershko C
Lancet; 1993 Apr; 341(8852):1088-9. PubMed ID: 8096975
[No Abstract] [Full Text] [Related]
6. Oral iron chelation therapy with deferiprone. Monitoring of biochemical, drug and iron excretion changes.
Kontoghiorghes GJ; Bartlett AN; Sheppard L; Barr J; Nortey P
Arzneimittelforschung; 1995 Jan; 45(1):65-9. PubMed ID: 7893273
[TBL] [Abstract][Full Text] [Related]
7. [Iron-chelating treatment].
Vullo C; Di Palma A; De Sanctis V; Borgatti L; Atti G
Haematologica; 1989 Oct; 74(5 Suppl):241-51. PubMed ID: 2512211
[No Abstract] [Full Text] [Related]
8. Efficacy and safety of 1-2, dimethyl-3-hydroxypyrid-4-one (L1) as an oral iron chelator in patients of beta thalassaemia major with iron overload.
Agarwal MB; Gupte SS; Vasandani D; Viswanathan C; Puniyani RR; Ramanathan J; Massil DE; Shah S; Rajyadhyaksha GC; Bhave AA
J Assoc Physicians India; 1991 Sep; 39(9):669-72. PubMed ID: 1814897
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and possible adverse effects of the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one (L1) in thalassemia major.
al-Refaie FN; Wonke B; Hoffbrand AV; Wickens DG; Nortey P; Kontoghiorghes GJ
Blood; 1992 Aug; 80(3):593-9. PubMed ID: 1638018
[TBL] [Abstract][Full Text] [Related]
10. Reduction of tissue iron stores and normalization of serum ferritin during treatment with the oral iron chelator L1 in thalassemia intermedia.
Olivieri NF; Koren G; Matsui D; Liu PP; Blendis L; Cameron R; McClelland RA; Templeton DM
Blood; 1992 May; 79(10):2741-8. PubMed ID: 1586721
[TBL] [Abstract][Full Text] [Related]
11. Blood disorders: future trends in iron chelation.
Jordan D; Kontoghiorghes G
Nurs Stand; 1990 Oct 24-30; 5(5):25-7. PubMed ID: 2124864
[TBL] [Abstract][Full Text] [Related]
12. New concepts of iron and aluminium chelation therapy with oral L1 (deferiprone) and other chelators. A review.
Kontoghiorghes GJ
Analyst; 1995 Mar; 120(3):845-51. PubMed ID: 7741239
[TBL] [Abstract][Full Text] [Related]
13. Effective chelation of iron in beta thalassaemia with the oral chelator 1,2-dimethyl-3-hydroxypyrid-4-one.
Kontoghiorghes GJ; Aldouri MA; Hoffbrand AV; Barr J; Wonke B; Kourouclaris T; Sheppard L
Br Med J (Clin Res Ed); 1987 Dec; 295(6612):1509-12. PubMed ID: 3122880
[TBL] [Abstract][Full Text] [Related]
14. L1 (1,2-dimethyl-3-hydroxypyrid-4-one) for oral iron chelation in patients with beta-thalassaemia major.
Töndury P; Kontoghiorghes GJ; Ridolfi-Lüthy A; Hirt A; Hoffbrand AV; Lottenbach AM; Sonderegger T; Wagner HP
Br J Haematol; 1990 Dec; 76(4):550-3. PubMed ID: 2265118
[TBL] [Abstract][Full Text] [Related]
15. Future of oral iron chelator deferiprone. (L1) ICOC committee.
Kontoghiorghes GJ; Agarwal MB; Tondury P; Kersten MJ; Jaeger M; Vreugdenhil G; Vania A; Rahman YE
Lancet; 1993 Jun; 341(8858):1479-80. PubMed ID: 8099176
[No Abstract] [Full Text] [Related]
16. Evaluation of the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one (L1) in iron-loaded patients.
Olivieri NF; Templeton DM; Koren G; Chung D; Hermann C; Freedman MH; McClelland RA
Ann N Y Acad Sci; 1990; 612():369-77. PubMed ID: 2291564
[No Abstract] [Full Text] [Related]
17. Long-term assessment of efficacy and safety of L1, an oral iron chelator, in transfusion dependent thalassaemia: Indian trial.
Agarwal MB; Gupte SS; Viswanathan C; Vasandani D; Ramanathan J; Desai N; Puniyani RR; Chhablani AT
Br J Haematol; 1992 Oct; 82(2):460-6. PubMed ID: 1419829
[TBL] [Abstract][Full Text] [Related]
18. The Importance and Essentiality of Natural and Synthetic Chelators in Medicine: Increased Prospects for the Effective Treatment of Iron Overload and Iron Deficiency.
Kontoghiorghes GJ
Int J Mol Sci; 2024 Apr; 25(9):. PubMed ID: 38731873
[TBL] [Abstract][Full Text] [Related]
19. Oral iron-chelating therapy: the L1 experience.
al-Refaie FN; Hoffbrand AV
Baillieres Clin Haematol; 1994 Dec; 7(4):941-63. PubMed ID: 7881161
[TBL] [Abstract][Full Text] [Related]
20. Zinc concentration in patients with iron overload receiving oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one or desferrioxamine.
al-Refaie FN; Wonke B; Wickens DG; Aydinok Y; Fielding A; Hoffbrand AV
J Clin Pathol; 1994 Jul; 47(7):657-60. PubMed ID: 8089225
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
